Day: December 28, 2019

The power supply to Hydro’s Paragominas bauxite mine has been resumed, allowing production to restart. Production is consequently being ramped up at Hydro’s Alunorte alumina refinery.On December 18, a transmission tower overturned, ceasing power supply to Paragominas, temporarily halting the production at the mine. The transmission tower has been repaired, and the power connection resumed.There were no personnel injuries, damages to other production assets or impact on the nearby environment related to the power outage.Financial and operational impact has been limited, and no negative customer impact is expected.  Investor contactContact Stian HasleCellular +47 97736022E-mail Stian.Hasle@hydro.comPress contactContact Halvor MollandCellular +47 92979797E-mail Halvor.Molland@hydro.com 

Strømtilførselen til Hydros bauksittgruve Paragominas i Brasil har blitt gjenopptatt og produksjonen har startet opp. Produksjonen ved Hydros aluminaraffineri Alunorte vil som en konsekvens også bli normalisert.  En høyspentmast som veltet 18. desember førte til strømbrudd for Paragominas og stanset midlertidig produksjonen ved gruven. Høyspentmasten har nå blitt reparert og strømtilførselen er gjenopprettet. Det var ingen personskader, skader på produksjonsutstyr eller innvirkning på nærmiljøet relatert til strømbruddet.Den finansielle og operasjonelle effekten fra strømstansen har vært begrenset og Hydro venter ikke at kunder blir negativt påvirket av strømstansen.InvestorkontaktStian Hasle+47 97736022Stian.Hasle@hydro.comPressekontaktHalvor...

Second BeiGene-discovered drug to receive regulatory approval, first in ChinaTislelizumab is an anti–PD-1 antibody specifically designed to minimize binding to FcγR on macrophagesBEIJING, China and CAMBRIDGE, Mass., Dec. 27, 2019 (GLOBE NEWSWIRE) — BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) as a treatment for patients with classical Hodgkin’s lymphoma (cHL) who have received at least two prior therapies. The new drug application (NDA) was previously granted priority review by the NMPA. Following the recent...

MONTREAL, Dec. 27, 2019 (GLOBE NEWSWIRE) — TC Transcontinental (TSX: TCL.A TCL.B) is proud to announce that Isabelle Marcoux, Chair of its Board of Directors, has been appointed Member of the Order of Canada. This is the second generation of this family of entrepreneurs to be granted this prestigious Canadian honour. Her father, Rémi Marcoux, founder of TC Transcontinental and a Director on its board, was invested into the Order of Canada himself in 2007. Like her father who founded the company, Ms. Marcoux is in turn deeply committed today to the sustained development of TC Transcontinental, a Québec Inc. corporation based in Montréal with a presence throughout North America, as well as within her community. Isabelle Marcoux’s career has been marked by many professional and philanthropic...

MONTRÉAL, 27 déc. 2019 (GLOBE NEWSWIRE) — TC Transcontinental (TSX : TCL.A TCL.B) est fière d’annoncer que la présidente de son conseil d’administration, Isabelle Marcoux, a été nommée Membre de l’Ordre du Canada. Il s’agit de la deuxième génération d’une même famille d’entrepreneurs à se voir remettre cette prestigieuse distinction honorifique canadienne. En effet, son père, Rémi Marcoux, fondateur de TC Transcontinental et administrateur, avait lui-même été investi de l’Ordre du Canada en 2007. À l’instar de son père qui a fondé l’entreprise, madame Marcoux est à son tour profondément engagée envers le développement...

TORONTO, Dec. 27, 2019 (GLOBE NEWSWIRE) — BlackRock Asset Management Canada Limited (“BlackRock Canada”), an indirect, wholly-owned subsidiary of BlackRock, Inc. (NYSE: BLK), today announced the final December cash distributions for the iShares ETFs listed on the TSX or NEO, with the exception of the iShares Premium Money Market ETF (“CMR”). Final cash distributions for CMR will be confirmed in a press release to be issued on or about December 30, 2019. Unitholders of record of a fund on December 31, 2019 will receive cash distributions payable in respect of that fund on January 6, 2020.Details regarding the “per unit” distribution amounts are as follows:(1) Distribution per unit amounts are USD for XAW.U, XDG.U, XDU.U, XEC.U, XEF.U, XFS.U, XMC.U, XMU.U, XUS.U, and XUU.U(2) DXZ had a 3:1 unit...